These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 24954228

  • 1. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
    Bennouna J, Havel L, Krzakowski M, Kollmeier J, Gervais R, Dansin E, Serke M, Favaretto A, Szczesna A, Cobo M, Ciuffreda L, Jassem J, Nicolini M, Ramlau R, Amoroso D, Melotti B, Almodovar T, Riggi M, Caux NR, Vaissière N, Tan EH.
    Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
    [Abstract] [Full Text] [Related]

  • 2. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [Abstract] [Full Text] [Related]

  • 3. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Pujol JL, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P, Corral J, San Antonio B, Chouaki N, John W, Zimmermann A, Visseren-Grul C, Gridelli C.
    Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
    [Abstract] [Full Text] [Related]

  • 4. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez M, Bell D, Biti G, Merimsky O, Beorchia A, Riggi M, Caux NR, Pouget JC, Dubray B, David P.
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [Abstract] [Full Text] [Related]

  • 5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J.
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [Abstract] [Full Text] [Related]

  • 9. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
    Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P.
    Cancer; 2015 Mar 15; 121(6):883-92. PubMed ID: 25377507
    [Abstract] [Full Text] [Related]

  • 10. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V.
    Cancer Chemother Pharmacol; 2015 Apr 15; 75(4):821-7. PubMed ID: 25702051
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer.
    Farhat FS, Ghosn MG, Kattan JG.
    Cancer Chemother Pharmacol; 2015 Aug 15; 76(2):235-42. PubMed ID: 26024554
    [Abstract] [Full Text] [Related]

  • 13. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V, Lorusso V, Galetta D, Caruso M M, Palomba G, Riccardi F, Borsellino N, Carrozza F, Leo S, Ferraù F, Cinieri S, Mancuso G, Mancarella S, Colucci G.
    Lung Cancer; 2010 Aug 15; 69(2):218-24. PubMed ID: 19910076
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.
    J Clin Oncol; 2009 Jul 10; 27(20):3284-9. PubMed ID: 19433684
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer.
    Zhang Q, Cai XW, Zhu ZF, Yu W, Liu Q, Feng W, Xue MC, Fu XL.
    Anticancer Drugs; 2015 Apr 10; 26(4):456-63. PubMed ID: 25646743
    [Abstract] [Full Text] [Related]

  • 17. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L.
    Lung Cancer; 2004 Oct 10; 46(1):87-98. PubMed ID: 15364136
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
    Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.
    J Clin Oncol; 2013 Aug 20; 31(24):3004-11. PubMed ID: 23835708
    [Abstract] [Full Text] [Related]

  • 20. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T.
    J Thorac Oncol; 2013 Dec 20; 8(12):1529-37. PubMed ID: 24389434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.